nach oben

Erschienen in:

08.12.2023 | Review

Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group

verfasst von: Laura Palagini, Raffaele Manni, Claudio Liguori, Luigi De Gennaro, Angelo Gemignani, Francesco Fanfulla, Raffaele Ferri, Lino Nobili, Luigi Ferini-Strambi

Erschienen in: Journal of Neurology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Insomnia is the most reported sleep disorder in industrialized countries, affecting, in the chronic form, around 10% of the European population. In Italy, such a percentage seems to be even higher. Although insomnia can be an independent disorder, it is frequently described as comorbid condition and may precipitate, exacerbate, or prolong a broad range of physical and mental disorders. Evaluating and targeting insomnia in the Italian clinical practice should be a priority.

Methods

The present expert opinions and recommendations represent an update from 2020 and insights from Insomnia Expert Consensus Group, based on systematic reviews according to PRISMA on available options in Italy from January 2020 to March 2023.

Results

We evaluated 28 papers among international guidelines, expert opinions, systematic reviews, and meta-analysis produced during the last 26 months.

Conclusions

Our findings suggest that symptoms of insomnia must be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions, and lifestyle. Cognitive behavioral therapy for insomnia should be the first option according to availability. The choice of the drug should be based on different factors including type of insomnia, age, comorbidities, and potential side effects. If the choice would be a Z-drug or a short-acting benzodiazepine (in subjects < 65 years old), the use should be in the short term (≤ 4 weeks). Indeed, eszopiclone, as a new option in Italy, may present a different profile and may be used for up to 6 months, also in the elderly. If the choice is melatonin, it should be used melatonin 2 mg prolonged release in adults ≥ 55 years for up to 13 weeks. A new dual orexin antagonist, daridorexant, is available in Italy; it has been shown to be effective in adults and elderly and it can be used for at least 3 months and up to 1 year.

American Psychiatric Association Sleep-Wake Disorders (2013) Diagnostic and statistical manual of mental disorders (DSM-5), 5th edn. American Psychiatric Association, ArlingtonCrossRef

American Psychiatric Association D-TF (2022) Diagnostic and statistical manual of mental disorders: DSM-5™. 5th Tex Revised ed. American Psychiatric Publishing, Inc., Washington

Riemann D, Benz F, Dressle RJ, Espie CA, Johann AF, Blanken TF, Leerssen J, Wassing R, Henry AL, Kyle SD, Spiegelhalder K, Van Someren EJW (2022) Insomnia disorder: State of the science and challenges for the future. J Sleep Res 31(4):e13604PubMedCrossRef

Ohayon MM, Smirne S (2002) Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med 3:115–120. https://doi.org/10.1016/S1389-9457(01)00158-7CrossRefPubMed

Terzano MG, Parrino L, Cirignotta F, Ferini-Strambi L, Gigli G, Rudelli G, et al. on behalf of the Studio Morfeo Committee (2004) Studio Morfeo: insomnia in primary care, a survey conducted on the Italian population. Sleep Med 5:67–75. https://doi.org/10.1016/j.sleep.2003.09.006

Terzano MG, Parrino L, Bonanni E, Cirignotta F, Ferrillo F, Gigli GL et al (2005) Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy. Clin Drug Investig 25:745–764. https://doi.org/10.2165/00044011-200525120-00002CrossRefPubMed

Proserpio P, Biggio G, Ferri R, Girardi P, Agostoni EC, Manni R, Minervino A, Palagini L, Plazzi G, Nobili L, Arnaldi D (2022) Insomnia in primary care: a survey conducted on Italian patients older than 50 years-results from the “Sonno e Salute” study. Neurol Sci 43(11):6487–6494PubMedPubMedCentralCrossRef

Hertenstein E, Feige B, Gmeiner T, Kienzler C, Spiegelhalder K, Johann A, Jansson-Fröjmark M, Palagini L, Rücker G, Riemann D, Baglioni C (2019) Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev 43:96–105. https://doi.org/10.1016/j.smrv.2018.10.006CrossRefPubMed

Palagini L, Hertenstein E, Riemann D, Nissen C (2022) Sleep, insomnia and mental health. J Sleep Res 31(4):e13628PubMedCrossRef

10.

Lin HT, Lai CH, Perng HJ, Chung CH, Wang CC, Chen WL, Chien WC (2018) Insomnia as an independent predictor of suicide attempts: a nationwide population-based retrospective cohort study. BMC Psychiatry 18(1):117PubMedPubMedCentralCrossRef

11.

Geoffroy PA, Oquendo MA, Courtet P, Blanco C, Olfson M, Peyre H, Lejoyeux M, Limosin F, Hoertel N (2021) Sleep complaints are associated with increased suicide risk independently of psychiatric disorders: results from a national 3-year prospective study. Mol Psychiatry 26(6):2126–2136PubMedCrossRef

12.

Hertenstein E, Trinca E, Wunderlin M, Schneider CL, Züst MA, Fehér KD, Su T, Straten AV, Berger T, Baglioni C, Johann A, Spiegelhalder K, Riemann D, Feige B, Nissen C (2022) Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. Sleep Med Rev 62:101597PubMedCrossRef

13.

Balestrieri M, Bortolomasi M, Galletta M, Bellantuono C (1997) Patterns of hypnotic prescription in Italy. A two-week community survey. Br J Psychiatry 170:176–180. https://doi.org/10.1192/bjp.170.2.176CrossRefPubMed

14.

Donato F, Samani F, Marini M, Mazzaglia G, Leggieri G, Balestrieri M et al (2001) A cross-sectional survey on benzodiazepine use among older people in an Italian region. J Public Health 2:42–48

15.

Ruggiero C, Lattanzio F, Dell’Aquila G, Gasperini B, Cherubini A (2009) Inappropriate drug prescriptions among older nursing home residents: the Italian perspective. Drugs Aging 1:15–30CrossRef

16.

Costa E, Sterzi E, Tedeschi F, Casari R, Marini P, Lugoboni F (2021) Can oral formulation increase the risk of lormetazepam abuse? Intern Emerg Med 16(3):785–788PubMedCrossRef

17.

Palagini L, Manni R, Aguglia E, Amore M, Brugnoli R, Girardi P, Grassi L, Mencacci C, Plazzi G, Minervino A, Nobili L, Biggio G (2020) Expert opinions and consensus recommendations for the evaluation and management of insomnia in clinical practice: joint statements of Five Italian Scientific Societies. Front Psychiatry 26(11):558CrossRef

18.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71PubMedPubMedCentralCrossRef

19.

Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U, Heald JL, Martin JL (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 17(2):255–262PubMedPubMedCentralCrossRef

20.

Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG et al (2017) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26:675–700PubMedCrossRef

21.

Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017) Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 13:307–349PubMedPubMedCentralCrossRef

22.

Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie CA, Gringras P, Krystal AD, Nutt D, Selsick H, Sharpley AL (2019) British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol 33:923–947PubMedCrossRef

23.

Palagini L, Manni R, Aguglia E, Amore M, Brugnoli R, Bioulac S, Bourgin P, Micoulaud Franchi JA, Girardi P, Grassi L, Lopez R, Mencacci C, Plazzi G, Maruani J, Minervino A, Philip P, Royant Parola S, Poirot I, Nobili L, Biggio G, Schroder CM, Geoffroy PA (2021) International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry 12:688890PubMedPubMedCentralCrossRef

24.

Rosenberg RP, Benca R, Doghramji P, Roth T (2023) A 2023 update on managing insomnia in primary care: insights from an expert consensus group. Prim Care Compan CNS Disord. 25(1):22nr03385CrossRef

25.

Takaesu Y, Sakurai H, Aoki Y, Takeshima M, Ie K, Matsui K, Utsumi T, Shimura A, Okajima I, Kotorii N, Yamashita H, Suzuki M, Kuriyama K, Shimizu E, Mishima K, Watanabe K, Inada K (2023) Treatment strategy for insomnia disorder: Japanese expert consensus. Front Psychiatry. 14:1168100PubMedPubMedCentralCrossRef

26.

Dikeos D, Wichniak A, Ktonas PY, Mikoteit T, Crönlein T, Eckert A, Kopřivová J, Ntafouli M, Spiegelhalder K, Hatzinger M, Riemann D, Soldatos C (2023) The potential of biomarkers for diagnosing insomnia: consensus statement of the WFSBP Task Force on Sleep Disorders. World J Biol Psychiatry 7:1–29

27.

De Crescenzo F, D’Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A (2022) Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 400(10347):170–184PubMedCrossRef

28.

Yue JL, Chang XW, Zheng JW, Shi L, Xiang YJ, Que JY, Yuan K, Deng JH, Teng T, Li YY, Sun W, Sun HQ, Vitiello MV, Tang XD, Zhou XY, Bao YP, Shi J, Lu L (2023) Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis. Sleep Med Rev 68:101746PubMedCrossRef

29.

Samara MT, Huhn M, Chiocchia V, Schneider-Thoma J, Wiegand M, Salanti G, Leucht S (2020) Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis. Acta Psychiatr Scand 142(1):6–17PubMedCrossRef

30.

Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J (2020) Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 76(3):363–381PubMedCrossRef

31.

Chiu HY, Lee HC, Liu JW, Hua SJ, Chen PY, Tsai PS, Tu YK (2021) Comparative efficacy and safety of hypnotics for insomnia in older adults: a systematic review and network meta-analysis. Sleep 44(5):260CrossRef

32.

Scharner V, Hasieber L, Sönnichsen A, Mann E (2022) Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr 22(1):87PubMedPubMedCentralCrossRef

33.

de Mendonça FMR, de Mendonça GPRR, Souza LC, Galvão LP, Paiva HS, de Azevedo Marques Périco C, Torales J, Ventriglio A, Castaldelli-Maia JM, Sousa Martins Silva A (2023) Benzodiazepines and sleep architecture: a systematic review. CNS Neurol Disord Drug Targ 22(2):172–179

34.

Baglioni C, Bostanova Z, Bacaro V, Benz F, Hertenstein E, Spiegelhalder K, Rücker G, Frase L, Riemann D, Feige B (2020) A systematic review and network meta-analysis of randomized controlled trials evaluating the evidence base of melatonin, light exposure, exercise, and complementary and alternative medicine for patients with insomnia disorder. J Clin Med 9(6):1949PubMedPubMedCentralCrossRef

35.

Morera-Fumero AL, Fernandez-Lopez L, Abreu-Gonzalez P (2020) Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review. Drug Alcohol Depend 1(212):107994CrossRef

36.

Marupuru S, Arku D, Campbell AM, Slack MK, Lee JK (2022) Use of melatonin and/on ramelteon for the treatment of insomnia in older adults: a systematic review and meta-analysis. J Clin Med 11(17):5138PubMedPubMedCentralCrossRef

37.

Choi K, Lee YJ, Park S, Je NK, Suh HS (2022) Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. Sleep Med Rev 66:101692PubMedCrossRef

38.

Maruani J, Reynaud E, Chambre J, Palagini L, Borigin P, Geoffroy PA (2023) Efficacy of melatonin and ramelteon o acute and long term management of insomnia disorder: a systematic revie and meta-analysis. J Sleep Res 23:195

39.

Almond SM, Warren MJ, Shealy KM, Threatt TB (2021) A systematic review of the efficacy and safety of over-the-counter medications used in older people for the treatment of primary insomnia. Sr Care Pharm 36(2):83–92PubMedCrossRef

40.

Zammit G, Dauvilliers Y, Pain S, Sebök Kinter D, Mansour Y, Kunz D (2020) Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 94(21):e2222–e2232PubMedCrossRef

41.

Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T, investigators (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 21(2):125–139. https://doi.org/10.1016/S1474-4422(21)00436-1CrossRefPubMed

42.

Robinson CL, Supra R, Downs E, Kataria S, Parker K, Kaye A, Viswanath O, Urits I (2022) Daridorexant for the treatment of insomnia. Health Psychol Res 10(3):37400PubMedPubMedCentralCrossRef

43.

Dos Santos JBR, da Silva MRR (2022) Daridorexant for the treatment of insomnia disorder: findings and implications. Eur J Clin Pharmacol 78(11):1749–1761PubMedCrossRef

44.

Jiang F, Li H, Chen Y, Lu H, Ni J, Chen G (2023) Daridorexant for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 102(7):e3275CrossRef

45.

Nie T (2023) Daridorexant in insomnia disorder: a profile of its use. CNS Drugs 37(3):267–274PubMedPubMedCentralCrossRef

46.

Ziemichód W, Grabowska K, Kurowska A, Biała G (2022) A comprehensive review of daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia. Molecules 27(18):6041PubMedPubMedCentralCrossRef

47.

Park J, Render PharmD KP, Cates PharmD DW (2023) Daridorexant: comprehensive review of a new oral agent for the treatment of insomnia. Ann Pharmacother 5:10600280221143794

48.

Xue T, Wu X, Li J, Chen S, Wang Z, Tan X, Wang Z, Zhang J (2023) Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. Front Pharmacol 14:1175372PubMedPubMedCentralCrossRef

49.

American Academy of Sleep Medicine (2014) International classification of sleep disorders-third edition (ICSD-3). American Academy of Sleep Medicine, Darien

50.

Lugaresi E, Cirignotta F, Zucconi M (1983) Good and poor sleepers: an epidemiological survey of the San Marino population. In: Guilleminault C, Lugaresi E (eds) Sleep/wake disorders: natural history, epidemiology, and long term evolution. Raven Press, New York

51.

Granella F, Spaggiari MC, Parrino L, Terzano MG (1995) Insonnia e uso di ipnoinducenti: studio epidemiologico sulla popolazione italiana. In: Di Perri R, Raffaele M, Silvestri R, Smirne S (eds) Il Sonno in Italia 1994. Poletto Editore, Milano, pp 2–11

52.

Espie C, Kyle SD, Hames P, Gardani M, Fleming L, Cape J (2014) The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder. BMJ Open 4:004183. https://doi.org/10.1136/bmjopen-2013-004183CrossRef

53.

Palagini L, Manni R (2016) Misurare il sonno. Minerva Medica, Torino

54.

Palagini L, Geoffroy PA, Gehrman PR, Miniati M, Gemignani A, Riemann D (2023) Potential genetic and epigenetic mechanisms in insomnia: a systematic review. J Sleep Res 14:e13868CrossRef

55.

Van Someren EJW (2021) Brain mechanisms of insomnia: new perspectives on causes and consequences. Physiol Rev 101(3):995–1046. https://doi.org/10.1152/physrev.00046.2019CrossRefPubMed

56.

Plante DT, Jensen JE, Winkelman JW (2012) The role of GABA in primary insomnia. Sleep 35:741–742. https://doi.org/10.5665/sleep.1854CrossRefPubMedPubMedCentral

57.

Palagini L, Bianchini C (2022) Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review. Front Neurosci 16:893015PubMedPubMedCentralCrossRef

58.

Tang S, Huang W, Lu S, Lu L, Li G, Chen X, Liu X, Lv X, Zhao Z, Duan R, Du Y, Tang J (2017) Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides 88:55–61. https://doi.org/10.1016/j.peptides.2016.12.008CrossRefPubMed

59.

Palagini L, Geoffroy PA, Balestrieri M, Miniati M, Biggio G, Liguori C, Menicucci D, Ferini-Strambi L, Nobili L, Riemann D, Gemignani A (2023) Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. J Sleep Res 32:e13825PubMedCrossRef

60.

Riemann D, Klein T, Rodenbeck A, Feige B, Horny A, Hummel R, Weske G, Al-Shajlawi A, Voderholzer U (2002) Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Res 113(1–2):17–27PubMedCrossRef

61.

Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL et al (2012) The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep 35:287–302. https://doi.org/10.5665/sleep.1642CrossRefPubMedPubMedCentral

62.

Morin CM (1993) Insomnia: psychological assessment and management. Guilford Press, New York

63.

Johns MW (1991) A new method of measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540. https://doi.org/10.1093/sleep/14.6.540CrossRefPubMed

64.

Vignatelli L, Plazzi G, Barbato A, Ferini-Strambi L, Manni R, Pompei F, D’Alessandro R, GINSEN (Gruppo Italiano Narcolessia Studio Epidemiologico Nazionale) (2003) Italian version of the Epworth sleepiness scale: external validity. Neurol Sci 23(6):295–300PubMedCrossRef

65.

Castronovo V, Galbiati A, Marelli S, Brombin C, Cugnata F, Giarolli L et al (2016) Validation study of the Italian version of the Insomnia Severity Index (ISI). Neurol Sci 37:1517–1524. https://doi.org/10.1007/s10072-016-2620-z[CrossRefPubMed

66.

Liguori C, Mombelli S, Fernandes M, Zucconi M, Plazzi G, Ferini-Strambi L, Logroscino G, Mercuri NB, Filardi M (2023) The evolving role of quantitative actigraphy in clinical sleep medicine. Sleep Med Rev 68:101762PubMedCrossRef

67.

Benz F, Knoop T, Ballesio A, Bacaro V, Johann AF, Rücker G, Feige B, Riemann D, Baglioni C (2020) The efficacy of cognitive and behavior therapies for insomnia on daytime symptoms: a systematic review and network meta-analysis. Clin Psychol Rev 80:101873PubMedCrossRef

68.

Thakral M, Von Korff M, McCurry SM, Morin CM, Vitiello MV (2020) Changes in dysfunctional beliefs about sleep after cognitive behavioral therapy for insomnia: a systematic literature review and meta-analysis. Sleep Med Rev 49:101230PubMedCrossRef

69.

Soh HL, Ho RC, Ho CS, Tam WW (2020) Efficacy of digital cognitive behavioural therapy for insomnia: a meta-analysis of randomised controlled trials. Sleep Med 75:315–325PubMedCrossRef

70.

Ma Y, Hall DL, Ngo LH, Liu Q, Bain PA, Yeh GY (2021) Efficacy of cognitive behavioral therapy for insomnia in breast cancer: a meta-analysis. Sleep Med Rev 55:101376PubMedCrossRef

71.

Selvanathan J, Pham C, Nagappa M, Peng PWH, Englesakis M, Espie CA, Morin CM, Chung F (2021) Cognitive behavioral therapy for insomnia in patients with chronic pain—a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 60:101460PubMedCrossRef

72.

Yu H, Zhang Y, Liu Q, Yan R (2021) Efficacy of online and face-to-face cognitive behavioral therapy in the treatment of neurological insomnia: a systematic review and meta-analysis. Ann Palliat Med 10(10):10684–10696PubMedCrossRef

73.

Squires LR, Rash JA, Fawcett J, Garland SN (2022) Systematic review and meta-analysis of cognitive-behavioural therapy for insomnia on subjective and actigraphy-measured sleep and comorbid symptoms in cancer survivors. Sleep Med Rev 63:101615PubMedCrossRef

74.

Simon L, Steinmetz L, Feige B, Benz F, Spiegelhalder K, Baumeister HS (2023) Comparative efficacy of onsite, digital, and other settings for cognitive behavioral therapy for insomnia: a systematic review and network meta-analysis. Sci Rep 13(1):1929PubMedPubMedCentralCrossRef

75.

Baglioni C, Altena E, Bjorvatn B, Blom K, Bothelius K, Devoto A et al (2019) The European Academy for cognitive behavioural therapy for insomnia: an initiative of the European Insomnia Network to promote implementation and dissemination of treatment. J Sleep Res 19:12967. https://doi.org/10.1111/jsr.12967CrossRef

76.

Espie CA (2013) Overcaming insomnia and sleep problems. A self-help guide using Cognitive Behavioural Techniques. In: Espie CA (ed) Superare L’insonnia. Come dormire meglio con la terapia cognitivo comportamentale, un metodo self help. Eclipsi Firenze 2013: Edizione italiana a cura di Laura Palagini

77.

Edinoff AN, Wu N, Ghaffar YT, Prejean R, Gremillion R, Cogburn M, Chami AA, Kaye AM, Kaye AD (2021) Zolpidem: efficacy and side effects for insomnia. Health Psychol Res 9(1):24927PubMedPubMedCentralCrossRef

78.

Nutt DJ, Stahl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 24:1601–1612. https://doi.org/10.1177/0269881109106927CrossRefPubMed

79.

Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV (2022) Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial. Drugs Aging 39(10):795–810PubMedPubMedCentralCrossRef

80.

Palagini L, Alfi G, Guerrieri R, Caruso V, Trivella M, Annuzzi E, Gambini M, Granno G, Miniati M, Gemignani A (2023) Early experience with the new DORA daridorexant in patients with insomnia disorder: results of a real world study with a 3 months follow up period. Sleep Med (in press)

81.

Fernandes M,Placidi F, Izzi F, Castelli A, Pagano A, Mercuri NB, Liguori C (2023) Daridorexant treatment effectiveness for chronic insomnia: a real world retrospective study. Sleep Med (in press)

Titel: Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group
verfasst von: Laura Palagini
Raffaele Manni
Claudio Liguori
Luigi De Gennaro
Angelo Gemignani
Francesco Fanfulla
Raffaele Ferri
Lino Nobili
Luigi Ferini-Strambi
Publikationsdatum: 08.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 4/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12112-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Herbert Coddington Major (1850–1921)

Progressive multifocal leukoencephalopathy in patients with chronic liver disease successfully treated with pembrolizumab

Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials

Evidence for converging pathophysiology in complex regional pain-syndrome and primary headache disorders: results from a case–control study

Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis